Answers are grounded in this paper and cite their sources.
In this work, a series of tetrahydropyrido[3,4-d]pyrimidine derivatives were rationally designed as HIV-1 non-nucleoside reverse transcriptase inhibitors via scaffold modification. Most compounds demonstrated promising potency against wild-type HIV-1 (IIIB) and clinically relevant mutants. Notably, 10p showed the strongest activity against HIV-1 IIIB, L100I, K103N, Y188C, Y188L, and E138K (EC50 = 2.4−16.5 nM). Importantly, 10p maintained potent efficacy against F227L/V106A (EC50 = 12.3 nM) and K103N/Y181C (EC50 = 21.7 nM). In vitro assessment revealed that the metabolic clearance rate of 10p in human liver microsomes was moderately lower than that of rilpivirine. Additionally, 10p showed a low potential for CYP-mediated drug interactions and had a negligible inhibitory effect on the hERG potassium channel. In the acute oral toxicity study in mice, no adverse effects were observed at a dose of up to 2000 mg/kg. These findings identify 10p as a promising lead compound for further development.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: